Lead Biologics
- Biotech or pharma, therapeutic R&D
Lead Biologics develops therapeutic antibodies for cancer immunotherapy by targeting a novel immune escape mechanism identified by the company founders.
Lead Biologics is a spin-out company from Lund University in Sweden focused on immuno-oncology. We have discovered a novel immune escape mechanism that is present in both acute myeloid leukemia (AML) and multiple types of solid tumors including colorectal cancer (CRC). Our lead candidate is a therapeutic antibody that targets this immune checkpoint and induces a potent and selective anti-cancer T cell response. We are now seeking a partner for further development into clinical phase and beyond.
All requests from service providers will be declined.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}